logo

FDA Calendar

Share
PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our premium biotech research product and our biotech home page.
Company Name
Ticker
Drug
Event
Date
Outcome
Details
Sanofi
Isatuximab (BLA)
FDA decision on Isatuximab b for the treatment of patients with relapsed/refractory multiple myeloma
04/30/2020
United Therapeutics Corp
Trevyent (UTHR)
FDA decision on Trevyent for the treatment of pulmonary arterial hypertension
04/27/2020
Correvio Pharma Corp.
Trevyent (NDA)
FDA decision on Trevyent for the treatment of pulmonary arterial hypertension
04/27/2020
Neurocrine Biosciences Inc
Opicapone (NDA)
FDA decision on Opicapone as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes.
04/26/2020
Sanofi
MenQuadfi (BLA)
FDA decision on MenQuadfi to prevent meningococcal meningitis
04/25/2020
AstraZeneca PLC
AZN.L, AZN
Trastuzumab deruxtecan (BLA)
FDA decision on Trastuzumab deruxtecan or treatment of patients with HER2-positive metastatic breast cancer
04/17/2020
Eli Lilly And Co.
Empagliflozin/Iinagliptin/Metformin Triple Combination Tablet (NDA)
FDA decision on the triple combination tablet for adults with Type 2 Diabetes
04/04/2020
Celgene Corporation
Luspatercept (BLA)
FDA decision on Luspatercept for adult patients with very low- to intermediate-risk MDS-associated anemia
04/04/2020
Acceleron Pharma, Inc
Luspatercept (BLA)
FDA decision on Luspatercept for adult patients with very low- to intermediate-risk MDS-associated anemia
04/04/2020
Rockwell Medical Technologies Inc
IV Triferic (NDA)
FDA decision on IV Triferic for iron deficiency in chronic kidney disease patients receiving hemodialysis
03/28/2020
IntelGenx Technologies Corp.
RIZAPORT VersaFilm (NDA)
FDA decision on RIZAPORT VersaFilm for the treatment of acute migraines
03/26/2020
Celgene Corporation
Ozanimod (NDA)
FDA decision on Ozanimod for Treatment of Relapsing Forms of Multiple Sclerosis
03/25/2020
Vertex Pharmaceuticals Inc.
VX-445 (elexacaftor), tezacaftor and ivacaftor triple therapy (NDA)
FDA decision on triple therapy to treat cystic fibrosis
03/19/2020
FDA approved the triple therapy, under brand name Trikafta, on October 21, 2019.
Eton Pharmaceuticals, Inc
ET-105 oral liquid (NDA)
FDA decision on ET-105 oral liquid for the treatment of various forms of epilepsy
03/17/2020
Astellas Pharma Inc.
Enfortumab vedotin (BLA)
FDA decision on Enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer
03/15/2020
Buy this Content


pharmadown-nov12.jpg The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.
pharmaup-nov12.jpg The following are some of today's top gainers in the healthcare sector.
arow-nov12.jpg The following are the healthcare stocks that hit a new 52-week high on Monday.
Read More
New Zealand-based medical cannabis startup Nature's Answer said it has teamed up with Colorado-based Medicine Man Technologies Inc. and MedPharm Holdings to provide organic cannabis products in New Zealand. Nature's Answer noted that the partnership with Medicine Man Technologies will accelerate...
Cannabis company Canopy Growth Corp. said Thursday that it will launch a new cannabis wellness company with Canadian rapper Drake in his hometown of Toronto. The new company, named More Life Growth Co., will be a fully licensed producer of cannabis. The More Life Growth Co was previously a wholly-owned...
Barrie, Ontario-based cannabis extractor MediPharm Labs (LABS.TO) (MEDIF.OB) has filed an application to list its common shares on the NASDAQ Stock Market. The listing of MediPharm's common shares on the NASDAQ remains subject to the approval of the NASDAQ.
Read More
>